Fluoguide AS
STO:FLUO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fluoguide AS
Income from Continuing Operations
Fluoguide AS
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Income from Continuing Operations
-kr39.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Income from Continuing Operations
kr963m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
24%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Income from Continuing Operations
kr6.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Income from Continuing Operations
-$21.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Income from Continuing Operations
-€228m
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-21%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Income from Continuing Operations
kr1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
38%
|
CAGR 10-Years
37%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Income from Continuing Operations?
Income from Continuing Operations
-39.5m
DKK
Based on the financial report for Dec 31, 2025, Fluoguide AS's Income from Continuing Operations amounts to -39.5m DKK.
What is Fluoguide AS's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-18%
Over the last year, the Income from Continuing Operations growth was -36%. The average annual Income from Continuing Operations growth rates for Fluoguide AS have been -13% over the past three years , -18% over the past five years .
